Global Human Coagulation Factor VIII Market Research Report 2023(Status and Outlook)

Global Human Coagulation Factor VIII Market Research Report 2023(Status and Outlook)



Report Overview

Human Coagulation Factor VIII is an essential blood-clotting protein, also known as anti-hemophilic factor (AHF). In humans, factor VIII is encoded by the F8 gene, defects in this gene results in hemophilia A. Human Coagulation Factor VIII concentrated from donated blood plasma (Aafact or Alphanate, Monoclate-P®), or alternatively recombinant Human Coagulation Factor VIII can be given to hemophiliacs to restore hemostasis.

Global Human Coagulation Factor VIII key players include Baxter, Bayer, CSL, Pfizer, Biogen, etc. Global top five manufacturers hold a share about 80%. North America is the largest market, with a share about 60%, followed by Europe, with a share about 30 percent. In terms of product, Recombinant Factor VIII is the largest segment, with a share about 65%. And in terms of application, the largest application is Hemophilia A, followed by Spontanous / Trauma, Surgical, etc.

The Global Human Coagulation Factor VIII Market Size was estimated at USD 9553.00 million in 2022 and is projected to reach USD 14651.18 million by 2029, exhibiting a CAGR of 6.30% during the forecast period.

Bosson Research’s latest report provides a deep insight into the global Human Coagulation Factor VIII market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, Porter’s five forces analysis, value chain analysis, etc.

The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Human Coagulation Factor VIII Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.

In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Human Coagulation Factor VIII market in any manner.

Global Human Coagulation Factor VIII Market: Market Segmentation Analysis

The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.

Key Company

Shire (Baxter)

Bayer

CSL

Pfizer

Grifols

Biogen

Octapharma

NovoNordisk

Greencross

Kedrion

BPL

Hualan Bio

RAAS

Market Segmentation (by Type)

Recombinant Factor VIII

Plasma-derived Factor VIII

Market Segmentation (by Application)

Biological & Pharmaceutical Application

Chemical & Oil Application

Other Applications

Geographic Segmentation

North America (USA, Canada, Mexico)

Europe (Germany, UK, France, Russia, Italy, Rest of Europe)

Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)

South America (Brazil, Argentina, Columbia, Rest of South America)

The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)

Key Benefits of This Market Research:

Industry drivers, restraints, and opportunities covered in the study

Neutral perspective on the market performance

Recent industry trends and developments

Competitive landscape & strategies of key players

Potential & niche segments and regions exhibiting promising growth covered

Historical, current, and projected market size, in terms of value

In-depth analysis of the Human Coagulation Factor VIII Market

Overview of the regional outlook of the Human Coagulation Factor VIII Market:

Key Reasons to Buy this Report:

Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change

This enables you to anticipate market changes to remain ahead of your competitors


1 Research Methodology and Statistical Scope
1.1 Market Definition and Statistical Scope of Human Coagulation Factor VIII
1.2 Key Market Segments
1.2.1 Human Coagulation Factor VIII Segment by Type
1.2.2 Human Coagulation Factor VIII Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 Human Coagulation Factor VIII Market Overview
2.1 Global Market Overview
2.1.1 Global Human Coagulation Factor VIII Market Size (M USD) Estimates and Forecasts (2018-2029)
2.1.2 Global Human Coagulation Factor VIII Sales Estimates and Forecasts (2018-2029)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 Human Coagulation Factor VIII Market Competitive Landscape
3.1 Global Human Coagulation Factor VIII Sales by Manufacturers (2018-2023)
3.2 Global Human Coagulation Factor VIII Revenue Market Share by Manufacturers (2018-2023)
3.3 Human Coagulation Factor VIII Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4 Global Human Coagulation Factor VIII Average Price by Manufacturers (2018-2023)
3.5 Manufacturers Human Coagulation Factor VIII Sales Sites, Area Served, Product Type
3.6 Human Coagulation Factor VIII Market Competitive Situation and Trends
3.6.1 Human Coagulation Factor VIII Market Concentration Rate
3.6.2 Global 5 and 10 Largest Human Coagulation Factor VIII Players Market Share by Revenue
3.6.3 Mergers & Acquisitions, Expansion
4 Human Coagulation Factor VIII Industry Chain Analysis
4.1 Human Coagulation Factor VIII Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 The Development and Dynamics of Human Coagulation Factor VIII Market
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Market Restraints
5.5 Industry News
5.5.1 New Product Developments
5.5.2 Mergers & Acquisitions
5.5.3 Expansions
5.5.4 Collaboration/Supply Contracts
5.6 Industry Policies
6 Human Coagulation Factor VIII Market Segmentation by Type
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Human Coagulation Factor VIII Sales Market Share by Type (2018-2023)
6.3 Global Human Coagulation Factor VIII Market Size Market Share by Type (2018-2023)
6.4 Global Human Coagulation Factor VIII Price by Type (2018-2023)
7 Human Coagulation Factor VIII Market Segmentation by Application
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Human Coagulation Factor VIII Market Sales by Application (2018-2023)
7.3 Global Human Coagulation Factor VIII Market Size (M USD) by Application (2018-2023)
7.4 Global Human Coagulation Factor VIII Sales Growth Rate by Application (2018-2023)
8 Human Coagulation Factor VIII Market Segmentation by Region
8.1 Global Human Coagulation Factor VIII Sales by Region
8.1.1 Global Human Coagulation Factor VIII Sales by Region
8.1.2 Global Human Coagulation Factor VIII Sales Market Share by Region
8.2 North America
8.2.1 North America Human Coagulation Factor VIII Sales by Country
8.2.2 U.S.
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Europe Human Coagulation Factor VIII Sales by Country
8.3.2 Germany
8.3.3 France
8.3.4 U.K.
8.3.5 Italy
8.3.6 Russia
8.4 Asia Pacific
8.4.1 Asia Pacific Human Coagulation Factor VIII Sales by Region
8.4.2 China
8.4.3 Japan
8.4.4 South Korea
8.4.5 India
8.4.6 Southeast Asia
8.5 South America
8.5.1 South America Human Coagulation Factor VIII Sales by Country
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Columbia
8.6 Middle East and Africa
8.6.1 Middle East and Africa Human Coagulation Factor VIII Sales by Region
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Egypt
8.6.5 Nigeria
8.6.6 South Africa
9 Key Companies Profile
9.1 Shire (Baxter)
9.1.1 Shire (Baxter) Human Coagulation Factor VIII Basic Information
9.1.2 Shire (Baxter) Human Coagulation Factor VIII Product Overview
9.1.3 Shire (Baxter) Human Coagulation Factor VIII Product Market Performance
9.1.4 Shire (Baxter) Business Overview
9.1.5 Shire (Baxter) Human Coagulation Factor VIII SWOT Analysis
9.1.6 Shire (Baxter) Recent Developments
9.2 Bayer
9.2.1 Bayer Human Coagulation Factor VIII Basic Information
9.2.2 Bayer Human Coagulation Factor VIII Product Overview
9.2.3 Bayer Human Coagulation Factor VIII Product Market Performance
9.2.4 Bayer Business Overview
9.2.5 Bayer Human Coagulation Factor VIII SWOT Analysis
9.2.6 Bayer Recent Developments
9.3 CSL
9.3.1 CSL Human Coagulation Factor VIII Basic Information
9.3.2 CSL Human Coagulation Factor VIII Product Overview
9.3.3 CSL Human Coagulation Factor VIII Product Market Performance
9.3.4 CSL Business Overview
9.3.5 CSL Human Coagulation Factor VIII SWOT Analysis
9.3.6 CSL Recent Developments
9.4 Pfizer
9.4.1 Pfizer Human Coagulation Factor VIII Basic Information
9.4.2 Pfizer Human Coagulation Factor VIII Product Overview
9.4.3 Pfizer Human Coagulation Factor VIII Product Market Performance
9.4.4 Pfizer Business Overview
9.4.5 Pfizer Human Coagulation Factor VIII SWOT Analysis
9.4.6 Pfizer Recent Developments
9.5 Grifols
9.5.1 Grifols Human Coagulation Factor VIII Basic Information
9.5.2 Grifols Human Coagulation Factor VIII Product Overview
9.5.3 Grifols Human Coagulation Factor VIII Product Market Performance
9.5.4 Grifols Business Overview
9.5.5 Grifols Human Coagulation Factor VIII SWOT Analysis
9.5.6 Grifols Recent Developments
9.6 Biogen
9.6.1 Biogen Human Coagulation Factor VIII Basic Information
9.6.2 Biogen Human Coagulation Factor VIII Product Overview
9.6.3 Biogen Human Coagulation Factor VIII Product Market Performance
9.6.4 Biogen Business Overview
9.6.5 Biogen Recent Developments
9.7 Octapharma
9.7.1 Octapharma Human Coagulation Factor VIII Basic Information
9.7.2 Octapharma Human Coagulation Factor VIII Product Overview
9.7.3 Octapharma Human Coagulation Factor VIII Product Market Performance
9.7.4 Octapharma Business Overview
9.7.5 Octapharma Recent Developments
9.8 NovoNordisk
9.8.1 NovoNordisk Human Coagulation Factor VIII Basic Information
9.8.2 NovoNordisk Human Coagulation Factor VIII Product Overview
9.8.3 NovoNordisk Human Coagulation Factor VIII Product Market Performance
9.8.4 NovoNordisk Business Overview
9.8.5 NovoNordisk Recent Developments
9.9 Greencross
9.9.1 Greencross Human Coagulation Factor VIII Basic Information
9.9.2 Greencross Human Coagulation Factor VIII Product Overview
9.9.3 Greencross Human Coagulation Factor VIII Product Market Performance
9.9.4 Greencross Business Overview
9.9.5 Greencross Recent Developments
9.10 Kedrion
9.10.1 Kedrion Human Coagulation Factor VIII Basic Information
9.10.2 Kedrion Human Coagulation Factor VIII Product Overview
9.10.3 Kedrion Human Coagulation Factor VIII Product Market Performance
9.10.4 Kedrion Business Overview
9.10.5 Kedrion Recent Developments
9.11 BPL
9.11.1 BPL Human Coagulation Factor VIII Basic Information
9.11.2 BPL Human Coagulation Factor VIII Product Overview
9.11.3 BPL Human Coagulation Factor VIII Product Market Performance
9.11.4 BPL Business Overview
9.11.5 BPL Recent Developments
9.12 Hualan Bio
9.12.1 Hualan Bio Human Coagulation Factor VIII Basic Information
9.12.2 Hualan Bio Human Coagulation Factor VIII Product Overview
9.12.3 Hualan Bio Human Coagulation Factor VIII Product Market Performance
9.12.4 Hualan Bio Business Overview
9.12.5 Hualan Bio Recent Developments
9.13 RAAS
9.13.1 RAAS Human Coagulation Factor VIII Basic Information
9.13.2 RAAS Human Coagulation Factor VIII Product Overview
9.13.3 RAAS Human Coagulation Factor VIII Product Market Performance
9.13.4 RAAS Business Overview
9.13.5 RAAS Recent Developments
10 Human Coagulation Factor VIII Market Forecast by Region
10.1 Global Human Coagulation Factor VIII Market Size Forecast
10.2 Global Human Coagulation Factor VIII Market Forecast by Region
10.2.1 North America Market Size Forecast by Country
10.2.2 Europe Human Coagulation Factor VIII Market Size Forecast by Country
10.2.3 Asia Pacific Human Coagulation Factor VIII Market Size Forecast by Region
10.2.4 South America Human Coagulation Factor VIII Market Size Forecast by Country
10.2.5 Middle East and Africa Forecasted Consumption of Human Coagulation Factor VIII by Country
11 Forecast Market by Type and by Application (2024-2029)
11.1 Global Human Coagulation Factor VIII Market Forecast by Type (2024-2029)
11.1.1 Global Forecasted Sales of Human Coagulation Factor VIII by Type (2024-2029)
11.1.2 Global Human Coagulation Factor VIII Market Size Forecast by Type (2024-2029)
11.1.3 Global Forecasted Price of Human Coagulation Factor VIII by Type (2024-2029)
11.2 Global Human Coagulation Factor VIII Market Forecast by Application (2024-2029)
11.2.1 Global Human Coagulation Factor VIII Sales (K MT) Forecast by Application
11.2.2 Global Human Coagulation Factor VIII Market Size (M USD) Forecast by Application (2024-2029)
12 Conclusion and Key Findings

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings